Cancer Therapy : Preclinical Cisplatin-Induced Renal Injury Is Independently Mediated by OCT 2 and p 53
暂无分享,去创建一个
A. Gibson | A. Sparreboom | E. Schlatter | J. Sprowl | G. Ciarimboli | N. Pabla | L. Janke | Lie Li | C. Lancaster | E. Hermann | A. Kosloske | Dorothea Zeeh | Navjotsingh Pabla | Cynthia S. Lancaster
[1] A. Gibson,et al. Conjunctive therapy of cisplatin with the OCT2 inhibitor cimetidine: influence on antitumor efficacy and systemic clearance , 2013, Clinical pharmacology and therapeutics.
[2] Taosheng Chen,et al. 146 Identification of Tyrosine Kinase Inhibitors as Modulators of OCT2 Function , 2012 .
[3] Jing Zhang,et al. Ameliorative effects of SLC22A2 gene polymorphism 808 G/T and cimetidine on cisplatin-induced nephrotoxicity in Chinese cancer patients. , 2012, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.
[4] Minoru Yoshida,et al. Effects of genetic variants in SLC22A2 organic cation transporter 2 and SLC47A1 multidrug and toxin extrusion 1 transporter on cisplatin-induced adverse events , 2012, Clinical and Experimental Nephrology.
[5] M. Relling,et al. Proximal Tubular Secretion of Creatinine by Organic Cation Transporter OCT2 in Cancer Patients , 2012, Clinical Cancer Research.
[6] Shuang Huang,et al. Inhibition of PKCδ reduces cisplatin-induced nephrotoxicity without blocking chemotherapeutic efficacy in mouse models of cancer. , 2011, The Journal of clinical investigation.
[7] F. Zunino,et al. Synthesis and biological evaluation of imidazolo[2,1-b]benzothiazole derivatives, as potential p53 inhibitors. , 2011, Bioorganic & medicinal chemistry.
[8] Jia Yu,et al. Protecting cisplatin-induced nephrotoxicity with cimetidine does not affect antitumor activity. , 2010, Biological & pharmaceutical bulletin.
[9] R. Franke,et al. Cisplatin-Induced Downregulation of OCTN2 Affects Carnitine Wasting , 2010, Clinical Cancer Research.
[10] R. Franke,et al. Influence of Oct1/Oct2-Deficiency on Cisplatin-Induced Changes in Urinary N-Acetyl-β-D-Glucosaminidase , 2010, Clinical Cancer Research.
[11] H. Koepsell,et al. Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions. , 2010, The American journal of pathology.
[12] A. Sparreboom,et al. Contribution of Organic Cation Transporter 2 (OCT2) to Cisplatin‐Induced Nephrotoxicity , 2009, Clinical pharmacology and therapeutics.
[13] R. Murphy,et al. The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity. , 2009, American journal of physiology. Renal physiology.
[14] J. Verweij,et al. Interaction of Cisplatin with the Human Organic Cation Transporter 2 , 2008, Clinical Cancer Research.
[15] F. Zunino,et al. Cyclic pifithrin-alpha sensitizes wild type p53 tumor cells to antimicrotubule agent-induced apoptosis. , 2008, Neoplasia.
[16] L. Benson,et al. Cisplatin and dimethyl sulfoxide react to form an adducted compound with reduced cytotoxicity and neurotoxicity. , 2008, Neurotoxicology.
[17] Z. Dong,et al. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. , 2008, Kidney international.
[18] Shuang Huang,et al. ATR-Chk2 Signaling in p53 Activation and DNA Damage Response during Cisplatin-induced Apoptosis* , 2008, Journal of Biological Chemistry.
[19] J. Megyesi,et al. Activation and involvement of p53 in cisplatin-induced nephrotoxicity. , 2007, American journal of physiology. Renal physiology.
[20] A. C. Santos,et al. Cisplatin-induced nephrotoxicity is associated with oxidative stress, redox state unbalance, impairment of energetic metabolism and apoptosis in rat kidney mitochondria , 2007, Archives of Toxicology.
[21] S. Masuda,et al. Cisplatin and Oxaliplatin, but Not Carboplatin and Nedaplatin, Are Substrates for Human Organic Cation Transporters (SLC22A1–3 and Multidrug and Toxin Extrusion Family) , 2006, Journal of Pharmacology and Experimental Therapeutics.
[22] Shuzhong Zhang,et al. Organic cation transporters are determinants of oxaliplatin cytotoxicity. , 2006, Cancer research.
[23] S. Masuda,et al. Association between tubular toxicity of cisplatin and expression of organic cation transporter rOCT2 (Slc22a2) in the rat. , 2005, Biochemical pharmacology.
[24] T. Ludwig,et al. Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. , 2005, The American journal of pathology.
[25] R. Gary,et al. The p53 inhibitor pifithrin-alpha forms a sparingly soluble derivative via intramolecular cyclization under physiological conditions. , 2005, Molecular pharmaceutics.
[26] Dong Wang,et al. Cellular processing of platinum anticancer drugs , 2005, Nature Reviews Drug Discovery.
[27] Paul Workman,et al. An evaluation of the ability of pifithrin-alpha and -beta to inhibit p53 function in two wild-type p53 human tumor cell lines. , 2005, Molecular cancer therapeutics.
[28] Z. Siddik,et al. Cisplatin: mode of cytotoxic action and molecular basis of resistance , 2003, Oncogene.
[29] M. J. van den Bent,et al. Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients , 2003, British Journal of Cancer.
[30] R. Salvi,et al. Pifithrin-alpha suppresses p53 and protects cochlear and vestibular hair cells from cisplatin-induced apoptosis. , 2003, Neuroscience.
[31] P. Devarajan,et al. Cisplatin nephrotoxicity: molecular mechanisms. , 2003, Cancer therapy.
[32] D. Barfuss,et al. Inhibition of basolateral transport and cellular accumulation of cDDP and N-acetyl-L-cysteine-cDDP by TEA and PAH in the renal proximal tubule , 2003, Cancer Chemotherapy and Pharmacology.
[33] V. Anisimov,et al. [Susceptibility of wild and knockout p53 FVB/N line mice to benz(a)pyrene-induced subcutaneous sarcoma]. , 2002, Voprosy onkologii.
[34] G. Ramesh,et al. TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. , 2002, The Journal of clinical investigation.
[35] J. Everitt,et al. Nephrotoxicity and hepatotoxicity induced by inhaled bromodichloromethane in wild-type and p53-heterozygous mice. , 2001, Toxicological sciences : an official journal of the Society of Toxicology.
[36] M V Chernov,et al. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. , 1999, Science.
[37] L. Donehower,et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours , 1992, Nature.
[38] G. Koren,et al. Renal handling of cisplatin: interactions with organic anions and cations in the dog. , 1991, Clinical and investigative medicine. Medecine clinique et experimentale.
[39] C. Coleman,et al. The use of probenecid as a chemoprotector against cisplatin nephrotoxicity , 1991, Cancer.
[40] M. Weiner,et al. Inhibition of cis-diamminedichloroplatinum secretion by the human kidney with probenecid. , 1984, Cancer research.
[41] D. Ross,et al. Reduction of the renal toxicity of cis-dichlorodiammineplatinum(II) by probenecid. , 1979, Cancer treatment reports.